Sigalos John T, Pastuszak Alexander W, Khera Mohit
Baylor College of Medicine, 1 Baylor Plaza, Houston, TX 77030, USA.
Center for Reproductive Medicine, Baylor College of Medicine, 1 Baylor Plaza, Room N730 Houston, TX 77030, USA; Scott Department of Urology, Baylor College of Medicine, 7200 Cambridge Street, Houston, TX 77030, USA.
Med Clin North Am. 2018 Mar;102(2):361-372. doi: 10.1016/j.mcna.2017.10.011. Epub 2017 Dec 6.
Hypogonadism is a common condition defined by the presence of low serum testosterone levels and hypogonadal symptoms, and most commonly treated using testosterone therapy (TTh). The accuracy of diagnosis and appropriateness of treatment, along with proper follow-up, are increasingly important given the large increase in testosterone prescriptions and the recent concern for cardiovascular (CV) risk associated with TTh. In March of 2015, the US Food and Drug Administration required that testosterone product labels disclose a potential CV risk, despite the evidence base for this association being weak and inconclusive. However, TTh may improve CV outcomes rather than increase risks.
性腺功能减退是一种常见病症，其定义为血清睾酮水平低且伴有性腺功能减退症状，最常用睾酮疗法（TTh）进行治疗。鉴于睾酮处方大幅增加以及近期对与TTh相关的心血管（CV）风险的关注，诊断的准确性、治疗的适当性以及适当的随访变得越来越重要。2015年3月，美国食品药品监督管理局要求睾酮产品标签披露潜在的CV风险，尽管这种关联的证据基础薄弱且尚无定论。然而，TTh可能改善心血管结局而非增加风险。
